Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul-Sep;44(3):185-190.
doi: 10.4103/jmp.JMP_54_18.

Correlation between Biological Effective Dose and Radiation-induced Liver Disease from Hypofractionated Radiotherapy

Angelo M Bergamo  1 , Kevin Kauweloa  2 , Gregory Gan  1 , Zheng Shi  2 , Janeen Daniels  2 , Richard Crownover  2 , Ganesh Narayanasamy  3 , Sotirios Stathakis  2 , Panayiotis Mavroidis  4 , Niko Papanikolaou  2 , Alonso Gutierrez  2
Affiliations

Correlation between Biological Effective Dose and Radiation-induced Liver Disease from Hypofractionated Radiotherapy

Angelo M Bergamo et al. J Med Phys. 2019 Jul-Sep.

Abstract

Background: The prevention of radiation-induced liver disease (RILD) is very significant in ensuring a safe radiation treatment and high quality of life.

Aims and objectives: The purpose of this study is to investigate the correlation of physical and biological effective dose (BED) metrics with liver toxicity from hypo-fractionated liver radiotherapy.

Materials and methods: 41 hypo-fractionated patients in 2 groups were evaluated for classic radiation-induced liver disease (RILD) and chronic RILD, respectively. Patients were graded for effective toxicity (post-treatment minus pre-treatment) using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Physical dose (PD) distributions were converted to BED. The V10Gy, V15Gy, V20Gy, V25Gy and V30Gy physical dose-volume metrics were used in the analysis together with their respective BED-converted metrics of V16.7Gy3, V30Gy3, V46.7Gy3, V66.7Gy3 and V90Gy3. All levels were normalized to their respective patient normal liver volumes (NLV) and evaluated for correlation to RILD. Results were measured quantitatively using R2 regression analysis.

Results: The classic RILD group had median follow-up time of 1.9 months and the average PD-NLV normalized V10Gy, V15Gy, V20Gy, V25Gy and V30Gy metrics per grade were plotted against RILD yielding R2 correlations of 0.84, 0.72, 0.73, 0.65 and 0.70, respectively while the BED-volume metrics of V16.7Gy3, V30Gy3, V46.7Gy3, V66.7Gy3 and V90Gy3 resulted in correlation values of 0.84, 0.74, 0.66, 0.78 and 0.74, respectively. BED compared to PD showed a statistically significant (p=.03) increase in R2 for the classic RILD group. Chronic RILD group had median follow-up time of 12.3 months and the average PD-NLV normalized V10Gy, V15Gy, V20Gy, V25Gy and V30Gy metrics per grade were plotted against RILD grade yielding R2 correlations of 0.48, 0.92, 0.88, 0.90 and 0.99 while the BED-volume metrics of V16.7Gy3, V30Gy3, V46.7Gy3, V66.7Gy3 and V90Gy3 resulted in correlation values of 0.43, 0.94, 0.99, 0.21 and 0.00, respectively.

Conclusion: The strong correlations of the V10Gy and V15Gy PD-volume metrics as well as the V16.7Gy3 (BED of V10Gy) to both classic and chronic RILD imply the appropriateness of the current 15Gy evaluation level for liver toxicity with hypo-fractionated treatments.

Keywords: Biological effective dose; Common Terminology Criteria for Adverse Events; hypofractionated; radiation-induced liver disease; stereotactic body radiation therapy; toxicity analysis.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Averaged physical and biological dose–volumes per grade plotted against classic and chronic radiation-induced liver disease with the regression values also shown
Figure 2
Figure 2
Box-and-whisker plots of the two most closely correlated dose-levels to classic radiation-induced liver disease corresponding to the V10Gy and V20Gy physical doses and the V16.7Gy3 and V66.7Gy3 biological effective dose values
Figure 3
Figure 3
Box-and-whisker plots of the two most closely correlated dose-levels to chronic radiation-induced liver disease corresponding to the V15Gy and V30Gy physical doses however, with the biological effective dose–volumes of V30Gy3 and V46.7Gy3
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008;26:657–64. - PubMed
    1. Lock MI, Hoyer M, Bydder SA, Okunieff P, Hahn CA, Vichare A, et al. An international survey on liver metastases radiotherapy. Acta Oncol. 2012;51:568–74. - PubMed
    1. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–8. - PubMed
    1. Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P, et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys. 2007;67:793–8. - PubMed
    1. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF, et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31:1237–48. - PubMed